Speaker：Simin Liu（刘斯敏）Yuxiang Huang（黄宇翔）Jinyi Han（韩瑾仪）Jiali Duan（段佳丽）Yimin Jian（简依敏）

Time：14:00 - 17:00

Location：Room 311, Kezhen Wang Building

Abstract:
2017 was a big year for immunotherapy, for two CAR-T therapies were approved by FDA. CAR-T method was exploding in the past 5 years, and has already made marvelous achievements from bench to bedside. In this Journal Club, we want to first revisit and trace back the development of CAR-T and take CD19 CAR-T as an example to see how a breakthrough in basic science be translated into clinic to save so much lives with such a high speed. Then we want to further dig out the current limitations of CAR-T in the CD19 case, including the cross-reaction issue. We will discuss at current stage we still feel desperate for most types of solid tumor. We will talk about five major challenges in the CAR T field: Trafficking, recognition, control, microenvironment and proliferation. Even if these challenges haven’t been overcome yet, we would like to lead a discussion on how to cope with them. Finally, we will end up with some discussion on opportunities in industry, especially the CAR T therapy in China.

Guest information:
1. Dr. Hong Wu (PKU)
http://www.cls.edu.cn/PrincipalInvestigator/pi/index2541.shtml
2. Dr. Jian Zhu (PKU)
http://cls.pku.edu.cn:8080/index.php?m=content&c=index&a=show&catid=81&id=58
3. Wen Si (Graduate student)

Recommend Literatures：
Review:
1. June, Carl H., et al. "CAR T cell immunotherapy for human cancer." Science 359.6382 (2018): 1361-1365.
Papers:
1. Cho, Jang Hwan, James J. Collins, and Wilson W. Wong. "Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses." Cell (2018).
2. Grupp, Stephan A., et al. "Chimeric antigen receptor–modified T cells for acute lymphoid leukemia." New England Journal of Medicine 368.16 (2013): 1509-1518.